Codeine disposition in sickle cell patients compared with healthy volunteers

Area of Science:

• Pharmacology and Drug Metabolism
• Clinical Pharmacokinetics
• Sickle Cell Disease Research

Background:

• Codeine pharmacokinetics are crucial for effective pain management in sickle cell patients (SCPs).
• Understanding drug disposition in SCPs is essential due to potential altered physiological conditions.
• Previous studies have not fully elucidated codeine's behavior in SCPs.

Purpose of the Study:

• To compare the pharmacokinetics of oral codeine sulfate between sickle cell patients and healthy controls.
• To investigate potential differences in codeine plasma protein binding in SCPs versus HCs.
• To determine the impact of these differences on codeine's elimination and half-life.

Main Methods:

• Oral codeine sulfate (60 mg) administered to SCPs and HCs.
• Plasma codeine concentrations measured using high-pressure liquid chromatography with fluorescence detection.
• Pharmacokinetic parameters (tmax, Cmax, AUC, Cl/F, MRT, t1/2) calculated via compartmental and noncompartmental analysis.
• In vitro and in vivo plasma protein binding of codeine assessed in both groups.

Main Results:

• No significant differences in tmax, Cmax, AUC, or Cl/F between SCPs and HCs.
• Significant differences observed in mean residence time (MRT) and half-life (t1/2) between groups.
• Markedly higher in vitro and in vivo plasma protein binding of codeine in SCPs (approx. 66-68%) compared to HCs (approx. 30%).

Conclusions:

• Increased codeine half-life in SCPs is likely due to altered volume of distribution, not clearance.
• Differences in plasma protein binding may contribute to altered codeine distribution in SCPs.
• Further research into volume of distribution and protein binding is warranted for optimizing codeine therapy in sickle cell disease.